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Heart transplantation (HTx) remains the unsurpassed standard of care for end-stage 
congestive heart failure (HF). HTx outcomes are benchmarks against which key outcome 
metrics of alternative lines of advanced HF management are compared to. Postoperative 
renal failure in non-renal solid organ transplant recipients leads to a fourfold increase in 
mortality [1]. Many perioperative factors converge to adversely affect renal function. 
These include preoperative renal dysfunction, suboptimal hemodynamics, and calcineurin 
inhibitor therapy [1]. Moreover, multiple comorbidities common to HTx candidates, such 
as hypertension and diabetes mellitus, act in concert to compromise renal function.  
Renal dysfunction is common among HTx candidates [2]. A consensus as to the degree 
of renal dysfunction that presents an absolute contraindication to isolated HTx is lacking, 
as evidenced by diverse worldwide institutional practices [3]. The introduction of 
combined heart and kidney transplantations has further challenged the contemporary 
indications for HTx, adding an entirely new layer of complexity to the process of patient 
selection [3]. Precise definition of the impact of renal dysfunction on post-HTx outcomes 
is, therefore, paramount to optimizing patient selection. A continuously increasing organ 
demand is contrasted by limited donor availability [4]. Patients who require dialysis in 
the acute postoperative period have been found to have a substantial increase in mortality 
that may reach 60-70% [5]. The occurrence of acute renal failure in close proximity to a 
cardiac surgical procedure is a major adverse event. No single strategy designed to 
prevent renal injury after cardiac surgery has been found to be unequivocally effective 
[5].  
We aimed to evaluate the independent effect of reduced functional renal reserve, 
quantified by pretransplant creatinine clearance, on 6-month survival and the requirement 
for acute renal replacement therapy (RRT) among patients undergoing isolated HTx.  
Data on all heart transplantations performed in Croatia from January 1, 2008 to 
November 1, 2014 were retrieved from two institutional electronic databases. Ethical 
standards in line with the Declaration of Helsinki were adhered to. The local Institutional 
Review Boards approved the study. Written informed consent was waived due to the 
study’s retrospective nature. 
During the study period 220 HTx were performed in Croatia. After harvesting data from 
electronic databases, individual medical records of HTx recipients were reviewed for 
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demographic, clinical, and laboratory data. Four patients were found to have missing data 
and were excluded. Accumulated donor variables included age and gender. Creatinine 
clearance (CrCl) values most proximal to the HTx procedure were used for estimating 
kidney function. CrCl was calculated using the Cockcroft-Gault formula. The primary 
end-point was 6-month posttransplant mortality. Secondary outcome measures were RRT 
within 30 days of Htx, stroke, resternotomy, incidence of postoperative mechanical 
circulatory assistance (MCS) and prolonged mechanical ventilation. Patients were 
dichotomized according to a CrCl cut-off value of 50 ml/min (Group A: CrCl≤50 ml/min; 
Group B: CrCl>50 ml/min). Propensity scores (PS) were calculated via logistic 
regression as the predicted probability of each patient’s group membership. The variables 
included in the PS adjustment were recipient age and gender, preoperative atrial 
fibrillation, smoking history, organ ischemic time, duration of cardiopulmonary bypass 
(CPB), body mass index, preoperative MCS and reoperation. We then incorporated the 
PS into a binary logistic regression model, thereby adjusting for the confounders.  
Sixty-three (29%) were found to have a CrCl≤50 ml/min. Patient characteristics are 
summarized in Table 1. Briefly, patients aggregated in Group A (CrCl≤50 ml/min) were 
older (56±11 vs. 49±12 years, P<0.001), and also had longer donor organ ischemic times 
(197±65 vs. 162±62 min, P<0.001). Dilated cardiomyopathy (CMP) was the most 
common pathology among patients with preserved preoperative renal functional reserve, 
followed by ischemic disease. Conversely, among patients with a CrCl≤50 ml/min 
ischemic CMP was the more prevalent pathology. The inter-group differences in the 
incidences of various cardiac pathologies antedating HTx were not statistically significant 
(Table 1).  
Six-month survival in the entire cohort was 83% (179/216). The overall incidence of 
posttransplant RRT was 15% (33/216). Acute postprocedural RRT (within 30 days of the 
index procedure) was required more commonly in patients with depressed pretransplant 
CrCl (16/63 (25%) vs. 17/153 (11%); OR 2.72 (1.28-5.82); P=0.012). The occurrence of 
dialysis-dependent renal failure led to a potent increase in mortality (20/33 (61%) vs. 
17/183 (9%); OR 15.02 [95% CI 6.37-35.44]; P <0.001). Of the 13 patients requiring 
acute RRT that were alive at 6 month follow-up, 12 recovered their renal function, while 
one patient remained dialysis dependent. Among patients with a CrCl≤50 ml/min 6-
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month mortality was higher than in patients with preserved renal function (18/63 (29%) 
vs. 19/153 (12%); unadjusted odds ratio (OR) 2.82 [95% CI 1.36-5.84]; P=0.009). No 
differences were observed in the incidence of stroke, resternotomy, postoperative MCS or 
prolonged mechanical ventilation (Table 2).  
A PS was determined by entering 9 covariates into a logistic regression model with CrCl 
as the dependent variable. All variables found to be statistically significantly different 
between the two studied cohorts on univariate analysis were included into the PS 
adjustment process. Additionally, we also included variables previously shown to exert 
an impact on outcome (recipient gender, reoperation, body mass index).  
Patients with a CrCl≤50 ml/min had increased 6-month mortality on the PS adjusted 
analysis (OR 2.44 [95% CI 1.09-5.49]; P=0.030). Similarly, the incidence of RRT 
remained higher among Group A patients after PS adjustment (OR 3.36 [95% CI 1.43-
7.92]; P=0.005). 
The expanding gap between organ demand and availability underscores the impetus for 
optimizing transplant recipient selection [6]. Controversial data on the impact of pre-HTx 
renal dysfunction on outcomes have been published [7,8,9,10]. Overall, renal dysfunction 
among HTx candidates (CrCl≤50 ml/min) was not uncommon in our practice. We have 
shown that the incidence of perioperative RRT was significantly increased among 
patients with reduced pre-HTx renal functional reserve. The profound negative impact of 
perioperative RRT on survival has been substantiated by our results. Most survivors who 
required dialysis in the acute postoperative period, however, recovered their renal 
function and were not dependent on RRT at 6-month follow-up.  
Survival was reduced in patients with reduced preoperative CrCl in our study. This effect 
remained significant after PS adjustment. These findings have important clinical 
implications as the proportion of high-risk patients enrolled into contemporary HTx 
programs is rising.  In summary, the strength of the relationship between pretransplant 
CrCl and the risk of acute renal failure mandating dialysis and death from any cause 
suggests that CrCl remains a valid prognostic marker among HTx candidates in the 
current era. 
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Table 1. Patient demographic and clinical data 
 
Patient characteristics 
Group A  
(CrCl≤50 ml/min), n=63 
Group B  
(CrCl>50 ml/min), n=153 
P 
Recipient age 
(years) 
56±11 49±12 <0.001 
Male recipients (n/%) 48 (76) 125 (82) 0.355 
Body mass index 
(kg/m
2
) 
25±4 26±5 0.257 
Donor age 
(years) 
39±11 39±12 0.875 
Male donors (n/%) 46 (73) 100 (65) 0.338 
PVR (dyn·s·cm−5) 213±107 188±96 0.145 
Hyperlipidemia (n/%) 22 (35) 55 (36) 1.0 
Hypertension (n/%) 28 (44) 62 (41) 0.650 
Diabetes mellitus 
(n/%) 
18 (29) 34 (22) 0.382 
Smoking history (n/%) 10 (16) 45 (29) 0.040 
Atrial fibrillation (n/%) 23 (37) 39 (25) 0.041 
Creatinine clearance 
(mL/min) 
39±8 75±18 <0.001 
Reoperation (n/%) 18 (29) 34 (22) 0.382 
Preoperative MCS 
(n/%) 
6 (10) 17 (11) 0.813 
Organ ischemic time 
(min) 
197±65 162±62 <0.001 
CPB time (min) 175±62 158±56 0.060 
Pretransplant cardiac 
pathology 
   
Dilated CMP 30 (48) 88 (58) 0.229 
Ischemic CMP 31 (49) 53 (35) 0.065 
Valvular CMP 0 (0) 2 (1) 1.0 
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Restrictive CMP 1 (2) 3 (2) 1.0 
Hypertrophic 
obstructive CMP 
0 (0) 2 (1) 1.0 
Left ventricular non-
compaction CMP 
0 (0) 2 (1) 1.0 
Grown-up congenital 
disease 
0 (0) 1 (1) 1.0 
ARVD 1 (2) 2 (1) 1.0 
 
CrCl = creatinine clearance, PVR = pulmonary vascular resistance, MCS = mechanical 
circulatory assistance, CPB = cardiopulmonary bypass, CMP = cardiomyopathy, ARVD = 
arrhythmogenic right ventricular dysplasia. 
 
 
  
 8 
 
Table 2. Analysis of perioperative outcomes   
 
Table 2A. Primary and secondary study outcomes on univariate analysis  
 Group A 
(CrCl ≤ 50 
mL/min), n=63 
 
Group B 
(CrCl>50 
ml/min), n=153 
Crude  
OR (95% CI) 
P 
6-month mortality 
(n/%) 
18 (29) 19 (12) 
2.82  
(1.36-5.84) 
0.009 
RRT (n/%) 16 (25) 17 (11) 
2.72  
(1.28-5.82) 
0.012 
Stroke (n/%) 
 
2 (3) 5 (3) 
0.97  
(0.18-5.14) 
1.0 
Resternotomy 
(n/%) 
 
15 (24) 24 (16) 
1.68  
(0.81-3.47) 
0.175 
Postoperative MCS 
(n/%) 
 
7 (11) 11 (7) 
1.61  
(0.60-4.37) 
0.417 
Prolonged 
mechanical 
ventilation (n/%) 
22 (35) 38 (25) 
1.62  
(0.86-3.06) 
0.137 
Table 2B. Primary and secondary study outcomes after propensity score adjustment 
 PS adjusted OR (95% CI) P 
6-month mortality (n/%) 2.44 (1.09-5.49) 0.030 
RRT (n/%) 3.36 (1.43-7.92) 0.005 
 
CrCl = creatinine clearance, OR = odds ratio, CI = confidence interval, RRT = renal replacement 
therapy, MCS = mechanical circulatory assistance, PS = propensity score  
